Cialis effective dose

Tadalafil.
Adult: As needed dosing: Initially, 10 mg as a single dose, taken at least 30 minutes before sexual activity; may be increased to 20 mg, or decreased to 5 mg depending on patient response and tolerability. Max dosing frequency: Once daily. In patients anticipating frequent use (e.g. at least twice weekly), a regular once-daily regimen with the lowest dose may be considered suitable. Regular daily dosing: 5 mg once daily, taken at the same time each day; may be decreased to 2.5 mg once daily depending on patient response and tolerability. Alternatively, start with 2.5 mg once daily, taken at the same time each day; may be increased to 5 mg once daily according to efficacy and tolerability. Periodically reassess the appropriateness of continued use of the daily regimen. Dosage recommendations may vary among individual products and between countries (refer to detailed product guideline).
Adult: 5 mg once daily, taken at the same time each day. For men being treated for both benign prostatic hyperplasia (BPH) and erectile dysfunction (ED): 5 mg once daily, taken at the same time each day; without regard to the timing of sexual activity.
Erectile dysfunction: Patients taking potent CYP3A4 inhibitors (e.g. ketoconazole, ritonavir): For as-needed dosing: Max: 10 mg once every 72 hours. For regular daily dosing: Max: 2.5 mg once daily.
Patients taking α-blockers: Initiate at the lowest recommended dose. Patient must be stable on α-blocker therapy before starting treatment.
Benign prostatic hyperplasia (with or without concomitant erectile dysfunction): Patients taking potent CYP3A4 inhibitors (e.g. ketoconazole, ritonavir): Max: 2.5 mg once daily.
Pulmonary arterial hypertension: Patients taking ritonavir for at least 1 week: Initially, 20 mg once daily, increased to 40 mg once daily as tolerated.
For concurrent use of ritonavir in patients taking tadalafil: Avoid use during ritonavir initiation; stop tadalafil treatment at least 24 hours before starting ritonavir. After at least 1 week of starting ritonavir, resume tadalafil at 20 mg once daily, increased to 20 mg once daily as tolerated.
Erectile dysfunction: Patient on haemodialysis: As needed dosing: Max: 5 mg once every 72 hours. Regular daily dosing: Not recommended. CrCl (mL/min) Dosage As needed dosing: Max: 5 mg once every 72 hours. Regular daily dosing: Not recommended. 30-50 As needed dosing: Initially, 5 mg once daily. Max: 10 mg once every 48 hours. Benign prostatic hyperplasia: Patient on haemodialysis: Not recommended. CrCl (mL/min) Dosage Not recommended. 30-50 For cases with or without concomitant erectile dysfunction: Initially, 2.5 mg once daily, may be increased up to Max 5 mg once daily if needed according to patient response. Pulmonary arterial hypertension: Patient on haemodialysis: Avoid. CrCl (mL/min) Dosage Avoid. 31-80 Initially, 20 mg once daily, may be increased to 40 mg once daily according to patient tolerability.
Erectile dysfunction: Mild to moderate (Child-Pugh class A or B): As needed dosing: Max: 10 mg taken before sexual activity, once daily. Severe (Child-Pugh class C): Not recommended.
Benign prostatic hyperplasia: Severe (Child-Pugh class C): Not recommended.
Pulmonary arterial hypertension: Mild to moderate (Child-Pugh class A or B): Initially, 20 mg once daily. Severe (Child-Pugh class C): Not recommended.
MI within the last 90 days, hypotension (
Patient with pre-existing CV disease or risk factors, left ventricular outflow obstruction (e.g. aortic stenosis, hypertrophic obstructive cardiomyopathy); anatomical penis deformation (e.g. angulation, cavernosal fibrosis, Peyronie’s disease); conditions which may be predisposed to priapism (e.g. sickle cell anaemia, multiple myeloma, leukaemia); risk factors of NAION (e.g. history of NAION, low cup-to-disc ratio [“crowded disc”], coronary artery disease, diabetes, hypertension, hyperlipidaemia, smoking, >50 years); peptic ulcer disease, bleeding disorders. Not recommended in patients with hereditary degenerative retinal disorders, including retinitis pigmentosa. When used for pulmonary arterial hypertension (PAH): Not recommended in patients with pulmonary veno-occlusive disease (PVOD), significant aortic or mitral valve disease, life-threatening arrhythmias, restrictive or congestive cardiomyopathy, coronary artery disease, significant left ventricular dysfunction, and pericardial constriction. Not indicated for use in women (when used for ED and BPH). Therapy in patients with severe renal impairment (CrCl.
Significant: Anginal chest pain, palpitations, tachycardia; impairment of colour discrimination (dose-related), hypotension; may worsen CV status of patients with PVOD. Rarely, sudden hearing loss (may be accompanied by dizziness and tinnitus), priapism or prolonged erections (>4 hours), sudden vision loss or NAION. Eye disorders: Blurred vision. General disorders and administration site conditions: Facial oedema. Gastrointestinal disorders: Dyspepsia, nausea, vomiting, abdominal pain, GERD. Immune system disorders: Hypersensitivity reactions. Musculoskeletal and connective tissue disorders: Back pain, pain in extremity, myalgia. Nervous system disorders: Headache, migraine, syncope. Reproductive system and breast disorders: Increased uterine bleeding. Respiratory, thoracic and mediastinal disorders: Nasal congestion, epistaxis, dyspnoea, nasopharyngitis, respiratory tract infection. Skin and subcutaneous tissue disorders: Rash, exfoliative dermatitis, Stevens-Johnson syndrome. Vascular disorders: Flushing. Potentially Fatal : Serious CV events (e.g. MI, stroke, TIA, sudden cardiac death, ventricular arrhythmia, unstable angina pectoris).